Мацитентан (ACT-064992)
Долгосрочное многоцентровое несравнительное открытое исследование - продолжение исследования SERENADE по оценке безопасности и эффективности мацитентана у пациентов с сердечной недостаточностью с сохранной фракцией выброса и поражением сосудов легких
Постоянная ссылка: https://clinomir.ru/trials/permit/ru/139/2019-03-22/
Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); Расчёт Клиномира. Что откуда
Простыми словами
Словарь терминов- Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 33 чел. в стране «Россия».
- Центров в реестре: 7 в 6 городах. Список — ниже на странице.
- Плановая дата окончания (04.2025) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 3 · невключение: 6
Критерии включения
- Signed and dated Informed Consent Form (ICF).
- Participant remained in the main study (SERENADE/AC-055G202, NCT03153111) for: a) 52 weeks after randomization if entered this Open-label (OL) extension study prior to protocol Version 4, b) At least 24 weeks after randomization if entering this OL extension study under protocol Version 4
- A woman of childbearing potential is eligible only if: (1) Negative pre-treatment serum pregnancy test; (2) Agreement to undertake monthly pregnancy tests from the enrollment visit up to at least 30 days after study treatment discontinuation; and (2) Agreement to use reliable contraception from at least 30 days prior to the enrollment visit up to at least 30 days after study treatment discontinuation.
Критерии невключения
- Premature discontinuation of study treatment in the main study (SERENADE/AC-055G202, NCT03153111) due to an adverse event related to: (1) Edema or fluid retention; (2) Worsening of heart failure; (3) Liver aminotransferase elevation; and (4) Study treatment, based on investigators' discretion
- Liver aminotransferase elevations, at the enrollment visit, fulfilling the following criteria: (1) Alanine amino transferase (ALT) / aspartate aminotransferase (AST) greater than or equal to (>=) 8 * the upper limit of normal (ULN); (2) ALT/AST >= 3 * ULN and associated clinical symptoms of liver injury, for example: nausea, vomiting, fever, abdominal pain, jaundice, unusual lethargy or fatigue, flu-like syndrome (arthralgia, myalgia, fever); and (3) ALT/AST >= 3 * ULN and associated increase in total bilirubin to >= 2 * ULN
- Treatment with the following forbidden medications within 1 month prior to the enrollment visit: (1) Treatments that may interfere with the assessment of efficacy (that is, endothelin receptor antagonists, prostanoids, phosphodiesterase-5 inhibitors, guanylate cyclase stimulators); (2) Strong cytochrome P-450 3A4 (CYP3A4) inducers such as rifabutin, rifampin, rifampicin, rifapentin, carbamazepine, phenobarbital, phenytoin, or St. John's wort; (3) Strong CYP3A4 inhibitors such as ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, nefazodone, ritonavir, and saquinavir or a moderate dual CYP3A4/CYP2C9 inhibitor (for example, fluconazole or amiodarone) or co-administration of a combination of moderate CYP3A4 (for example, ciprofloxacin, cyclosporine, diltiazem, erythromycin, verapamil) and moderate CYP2C9 inhibitors (for example, miconazole, piperine), in the 1-month period prior to baseline. This will not necessarily apply to participants who are already well-managed on such an ongoing combination; and (4) any other investigational treatment
- Pregnant, planning to be become pregnant or lactating.
- Any known factor or disease that might interfere with treatment compliance, study conduct, or interpretation of the results, such as drug or alcohol dependence or psychiatric disease.
- Known hypersensitivity to macitentan or drugs of the same class, or any of the study drug excipients (for example, soy lecithin, lactose)
Источник: ClinicalTrials.gov, NCT03714815 · запись обновлена в реестре 4 февраля 2025.
Дизайн и результаты
Что измеряют — первичные конечные точки (10)
- Number of Participants With All-cause Deaths up to 30 Days After Study Treatment Discontinuation — Up to 30 days after study treatment discontinuation (treatment exposure ranged from 0.4 to 126 weeks)
- Number of Participants With All-cause Hospital Admissions up to 30 Days After Study Treatment Discontinuation — Up to 30 days after study treatment discontinuation (treatment exposure ranged from 0.4 to 126 weeks)
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) up to 30 Days After Study Treatment Discontinuation — Up to 30 days after study treatment discontinuation (treatment exposure ranged from 0.4 to 126 weeks)
- Number of Participants With TEAEs Leading to Premature Discontinuation of Study Treatment — Up to 30 days after study treatment discontinuation (treatment exposure ranged from 0.4 to 126 weeks)
- Change From Baseline in Systolic and Diastolic Arterial Blood Pressure (BP) at Week 24 — Baseline and Week 24
- Change From Baseline in Systolic and Diastolic Arterial Blood Pressure (BP) at Week 52 — Baseline and Week 52
- Change From Baseline in Pulse Rate at Week 24 — Baseline and Week 24
- Change From Baseline in Pulse Rate at Week 52 — Baseline and Week 52
- Change From Baseline in Body Weight at Week 24 — Baseline and Week 24
- Change From Baseline in Body Weight at Week 52 — Baseline and Week 52
Цель исследования
The aim of this open-label (OL) extension trial is to study the long-term safety and efficacy of macitentan in subjects with heart failure with preserved ejection fraction (HFpEF) and pulmonary vascular disease (PVD) beyond the treatment in the double-blind parent SERENADE study (AC-055G202, NCT03153111). Furthermore, this OL extension study will give eligible subjects of the main study (SERENADE/AC-055G202, NCT03153111) an opportunity to continue or start receiving macitentan.
Области и заболевания
Где проходит
7 центров в 6 городахОткуда эта информация
-
ГРЛС — Государственный реестр лекарственных средств Минздрава России · № 139 от 22.03.2019 Официальный реестр · загружено 1 октября 2026Препарат, номер протокола, название, разрешение, фаза, сроки, число участников, спонсор, разработчик
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT03714815 Официальный реестр (США) · загружено 9 ноября 2026Цель, центры
-
Расчёт Клиномира По датам из реестраСтатус
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.